Related Experiment Video

Updated: May 10, 2025

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

7.9K

MicroRNAs as Sensitizers of Tyrosine Kinase Inhibitor Resistance in Cancer: Small Molecule Partnerships

Alma D Campos-Parra1, David Sánchez-Marín2, Víctor Acevedo-Sánchez1

  • 1Instituto de Salud Pública, Universidad Veracruzana (UV), Xalapa 91190, Mexico.

Pharmaceuticals (Basel, Switzerland)
|April 26, 2025
PubMed

Insights

MicroRNAs (miRNAs) can enhance cancer patients' sensitivity to tyrosine kinase inhibitors (TKIs). This review proposes a workflow to select optimal miRNA candidates, overcoming challenges in TKI-miRNA combination therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Tyrosine kinase inhibitors (TKIs) have improved cancer patient survival but face resistance.
  • MicroRNAs (miRNAs) show potential in overcoming TKI resistance.
  • Selecting optimal miRNAs for clinical use is a significant challenge due to their broad targeting.

Purpose of the Study:

  • To review how miRNAs enhance TKI sensitivity in various cancers.
  • To highlight challenges and limitations in TKI-miRNA combination therapies.
  • To propose a workflow for selecting suitable miRNA candidates for clinical trials.

Main Methods:

  • Literature review on miRNA-mediated TKI sensitization.
  • Analysis of challenges in miRNA-TKI therapeutic strategies.
  • Proposal of a bioinformatics-guided workflow for miRNA candidate selection.

Main Results:

  • miRNAs can re-sensitize cancer cells to TKIs across different cancer types.
  • Significant challenges exist in selecting specific miRNAs for effective combination therapy.
  • Bioinformatics tools can aid in identifying optimal miRNA candidates.

Conclusions:

  • A systematic approach is needed to select miRNAs for TKI combination therapy.
  • The proposed workflow aims to facilitate the development of successful TKI-miRNA therapeutics.
  • Further research is supported by this proposal for clinical translation.
Keywords:
TKIscancermiRNAsovercome resistancesensitizing

More Related Videos

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

14.8K
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

10.5K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.3K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
11.7K